• ACTION3 Phase 3 clinical trial adult cohort fully recruited with 333 patients
• Blinded review confirms study remains appropriately powered (>90%) to demonstrate treatment effect
• Dimerix in late-stage discussions for up to US$50 million (~A$70 million) in non-dilutive funding

Dimerix Limited, a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, has announced its Appendix 4C and Quarterly Activities Report for the period ended 31 March 2026. During the quarter, the company continued to progress the ACTION3 Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS), with the last adult patient now having received their first dose of DMX-200, marking a full transition from recruitment into treatment and follow-up across the global study. Dimerix also completed a blinded review of statistical assumptions for ACTION3, which provided confidence that the study remains appropriately powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria. To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint. The company is in late-stage discussions with multiple parties and has received terms to access up to US$50 million (~AU$70 million) in non-dilutive funding, which would deliver access to non-dilutive funding and extend the company's cash runway to support expanded access programs, commercial manufacturing activities, and building a sustainable pipeline of assets in rare and/or renal disease.

Dimerix may become eligible for up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales, across all its licences, with over $65 million in total payments already being received.

Dimerix is focused on developing its lead Phase 3 product candidate DMX-200 for FSGS kidney disease, with the ACTION3 Phase 3 trial having completed adult recruitment and the last patient expected to receive their last dose in Q1 2028. The company continues to progress its advanced licensing discussions with potential partners in territories not already licensed.